I find it odd that Tirz came out ahead of Reta on the weight difference.
There's a BMJ publication from July 2026 covering this exact topic.
Participants note the difference may stem from higher discontinuation rates with retatrutide rather than true efficacy gaps. The meta-analysis gives tirzepatide a reliable confidence interval while retatrutide has low or no certainty due to limited studies. Overlapping bars on the graph indicate no meaningful difference between them. Forum users suggest pooling individual weight-loss data to build a clearer picture beyond published trials.
What this discussion establishesWhether the tirzepatide advantage comes mainly from lower discontinuation or from data limitations on retatrutide
Still openHow the two drugs would truly compare with more retatrutide studies and lower dropout rates
Nothing here is advice.
There's a BMJ publication from July 2026 covering this exact topic.
I find it odd that Tirz came out ahead of Reta on the weight difference.
It could be the higher rate of people stopping Reta, not the drug's actual performance.
The analysis factors in variation across the studies. Tirz has enough trials for a trustworthy interval while Reta sits at low or no certainty because data are still thin. Checking whether the bars overlap on the figure gives a quick sense they are comparable and avoids running full stats. Forum members have plenty of personal numbers but rarely pool them, which leaves room for bias since people don't naturally track spread well. Gathering details on how much weight each person lost and over what period would probably beat the trial totals.
That lines up with what the figure displays, particularly the fatigue numbers for Reta.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.